In 2017 we took some of the most important steps in Paxman’s history. We launched operations in the US following the FDA clearance in April 2017, and we listed our parent company on Nasdaq First North Growth Market in Sweden in June 2017.
These were incredibly proud moments for the Paxman family and highlights the exciting future that Paxman has ahead. But this also keeps us focused on why the company started, with the wife of our founder, and the family’s determination to reduce this burdensome side effect for patients around the world.

We ask you to join us in this mission.

This decision to list the company was taken to support the company’s continued growth and most importantly to capitalise on our FDA clearance in the USA in April 2017. This in turn will lead to greater access to scalp cooling for patients around the world, whilst providing strong and sustainable growth for the business.

In preparation for the listing, an oversubscribed share issue of approximately SEK 30,4 million was conducted. The share price has reflected the company’s strong progression and has continued to strengthen highlighting the exciting potential of Paxman.

At Paxman, we are not only building a strong and financially viable business but improving the lives of cancer patients around the world. This is both a financial and social investment.

Together we are changing the face of cancer.